Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03800420 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

A Phase 2 study, sponsored by Bridge Biotherapeutics.

Terminated
Registry status
Phase 2
Development phase
16
Enrollment target

NCT03800420: Clinical Trial Phase 2 study, sponsored by Bridge Biotherapeutics.

NCT03800420 is a Phase 2 study that was terminated before completion, run by Bridge Biotherapeutics. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03800420, a Phase 2 study, was terminated before completion, sponsored by Bridge Biotherapeutics.

TERMINATED
Registry status
Phase 2
Development phase
16 participants
Enrollment target

Study Summary

This is randomized, placebo-controlled, dose-escalation, multicenter, Phase 2 study to evaluate the efficacy and safety of BBT-401-1S in patients with active ulcerative colitis. This study consists of three cohorts with 16-week treatment period per cohort that will be conducted sequentially.

Primary Outcome

The Total Mayo score is an instrument designed to measure disease activity of ulcerative colitis, with scores ranging from 0 to 12 points. The Total Mayo score consists of 4 subscores( Stool frequency, Rectal bleeding, Findings of endoscopy, Physician global assessment), each graded from 0 to 3 with higher scores indicating more severe disease.

Interventions

  • DRUG BBT-401-1S first and then Placebo
  • DRUG Placebo first and then BBT-401-1S

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2019-04-22
Est. Completion 2020-07-31
Phase Phase 2
Bridge Biotherapeutics

7 total trials

Why NCT03800420 stopped before completion

NCT03800420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 2 interventions - of which BBT-401-1S first and then Placebo is the first listed.

NCT03800420 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03800420 about?

NCT03800420 is a clinical study titled "Efficacy and Safety of BBT-401-1S in Ulcerative Colitis". This is randomized, placebo-controlled, dose-escalation, multicenter, Phase 2 study to evaluate the efficacy and safety of BBT-401-1S in patients with active ulcerative colitis. This study consists of three cohorts with 16-week treatment period per cohort that will be conducted sequentially.

What is the current status of trial NCT03800420?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2019-04-22. Estimated completion is 2020-07-31.

What interventions are being tested in trial NCT03800420?

The interventions under investigation include: BBT-401-1S first and then Placebo (DRUG), Placebo first and then BBT-401-1S (DRUG).

Who is sponsoring clinical trial NCT03800420?

This trial is sponsored by Bridge Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03800420's enrollment target sits among peer trials

16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-07-11

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT03824652 · started 2019-04-22 · Phase 2

    WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

  • NCT03710421 · started 2019-04-23 · Phase 1

    CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

  • NCT03752840 · started 2019-04-21 · NA

    Village-Integrated Eye Worker Trial II

  • NCT03835767 · started 2019-04-19 · Phase 2

    Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

Source: ClinicalTrials.gov NCT03800420, the US trial registry maintained by the National Library of Medicine. NCT03800420 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.